InsiderSignal.AI

InsiderSignal.ai

ADPT - Adaptive Biotechnologies Corp

Insider Sale by Robins Harlan S (Chief Scientific Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Robins Harlan S, serving as Chief Scientific Officer at Adaptive Biotechnologies Corp (ADPT), sold 470,266 shares at $13.17 per share, for a total transaction value of $6,193,403.00. Following this transaction, Robins Harlan S now holds 1,522,058 shares of ADPT.

This sale represents a 24.00% decrease in Robins Harlan S's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, March 11, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 13, 2026, 2 days after the trade was made.

Adaptive Biotechnologies Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Robins Harlan S

Chief Scientific Officer

Harlan S. Robins, PhD, is the Chief Scientific Officer and co-founder of Adaptive Biotechnologies Corporation (ADPT), a commercial-stage biotech company focused on translating the genetics of the adaptive immune system into clinical diagnostics and therapeutics for diseases like cancer.[[1]](https://fintool.com/app/research/companies/ADPT/people/harlan-robins)[[2]](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/)[[7]](https://www.adaptivebiotech.com/who-we-are/) He recently sold 10,000 shares of ADPT stock on January 6, valued at $164,000, as part of insider trading activity.[[8]](https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-cso-robins-sells-164k-in-shares-93CH-4438369) Robins earned a BS in Physics from Harvard University, an MS and PhD in Physics from UC Berkeley, and held postdoctoral appointments at the Weizmann Institute of Science and the Institute for Advanced Study at Princeton, where he developed bioinformatics algorithms for micro-RNA targets and bacterial genome analysis.[[1]](https://fintool.com/app/research/companies/ADPT/people/harlan-robins)[[2]](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/) Prior to Adaptive, he advanced through roles at the Fred Hutchinson Cancer Research Center's Computational Biology Program: Assistant Faculty (2006–2011), Associate (2011–2016), and Full Member/Program Head (2016–2019), pioneering immune profiling and immunogenomics technologies that underpin Adaptive's innovations.[[1]](https://fintool.com/app/research/companies/ADPT/people/harlan-robins)[[2]](https://www.adaptivebiotech.com/adaptive-leadership/harlan-robins/)[[4]](https://www.pmwcintl.com/speaker/harlan-robins_21_2021covid/) In 2009, alongside his brother Chad Robins (CEO), he co-founded Adaptive as a spinout from Fred Hutch to commercialize immunosequencing of T- and B-cell receptors.[[3]](https://www.youtube.com/watch?v=Ac5l9xSyUq8)[[7]](https://www.adaptivebiotech.com/who-we-are/)

View full insider profile →

Trade Price

$13.17

Quantity

470,266

Total Value

$6,193,403.00

Shares Owned

1,522,058

Trade Date

Wednesday, March 11, 2026

4 days ago

SEC Filing Date

Friday, March 13, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Adaptive Biotechnologies Corp

Company Overview

No company information available
View news mentioning ADPT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4757851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime